Effect of Rosiglitazone Maleate on inflammation following cerebral ischemia/reperfusion in rats

被引：0

作者：

Nanxiang Xiong

Fan Sun

Hongyang Zhao

Jizhou Xiang

机构：

[1] Huazhong University of Science and Technology,Department of Neurosurgery, Union Hospital, Tongji Medical College

[2] Huazhong University of Science and Technology,Department of Pharmacology, School of Basic Medical Sciences, Tongji Medical College

来源：

Journal of Huazhong University of Science and Technology | 2007年 / 27卷

关键词：

Rosiglitazone Maleate; rat; brain ischemia; myeloperoxidase; interleukin-6;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

In order to evaluate the neuroprotective effect of Rosiglitazone Maleate (RSG) against brain ischemic injury, the effects of Rosiglitazone Maleate on the inflammation following cerebral ischemia/reperfusion were investigated. Focal cerebral ischemia was induced by the intraluminal thread for cerebral middle artery (MCA) occlusion. Rosiglitazone Maleate at concentrations of 0.5, 2 and 5 mg/kg was infused by intragastric gavage twice immediately and 2 h after MCA occlusion, respectively. The effects of Rosiglitazone Maleate on brain swelling, myeloperoxidase and interleukin-6 mRNA level in brain tissue after MCA occlusion and reperfusion were evaluated. The results showed that as compared with the model control group, RSG (0.5 mg/kg) had no significant influence on brain swelling (P>0.05), but 2 mg/kg and 5 mg/kg RSG could significantly alleviate brain swelling (P<0.05). All different doses of RSG could obviously reduce MPO activity in brain tissue after MCA occlusion and reperfusion in a dose-dependent manner. RSG (0.5 and 2 mg/kg) could decrease the expression levels of IL-6 mRNA in brain tissue after MCA occlusion and reperfusion to varying degrees (P<0.05) with the difference being significant between them. It was concluded that RSG could effectively ameliorate brain ischemic injury after 24 h MCA occlusion and inhibit the inflammatory response after ischemia-reperfusion in this model.

引用

页码：295 / 298

页数：3

共 26 条

[1]

Campbell I. W.(2005)The clinical significance of PPAR gamma agonism Curr Mol Med 5 349-363

[2]

Ito K.(2004)Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats Eur J Cadiothorac Surg 25 530-536

[3]

Shimada J.(2003)Pioglitazone, a peroxisome oxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injuy in a rat model Lab Invest 83 1715-1721

[4]

Kato D.(2005)Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock Cardiovasc Res 65 772-781

[5]

Ito H.(1998)Inflammation and acute stroke Curr Opin Neurol 11 45-49

[6]

Nakano A.(1998)Leukocytes accumulate in the cerebral microcirculation during the first hour of reperfusion following stroke FASEB J 12 188-196

[7]

Kinoshita M.(2005)Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway Mol Pharmacol 67 1620-1628

[8]

Abdelrahman M.(2005)Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells Thromb Haemost 93 810-815

[9]

Sivarajah A.(2005)PPAR gamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells Atherosclerosis 183 163-167

[10]

Thiemermann C.(2005)Pioglitazone inhibits MMP-1 expression in vascular smooth muscle cells through a mitogen-activated protein kinase-independent mechanism Atherosclerosis 178 249-256

← 1 2 3 →